ALLMedicine™ Erythroleukemia Center

May 18th, 2022 - Background Solanine was primarily known as a toxic compound. Nonetheless, recently the apoptotic role of solanine through suppression of PI3K/AKT/mTOR signaling pathway has been shown against many malignancies except chronic myelogenous leukemia (...

Apr 15th, 2022 - Leukemic transformation (LT) of myeloproliferative neoplasm (MPN) has a dismal prognosis and is largely fatal. Mutational inactivation of TP53 is the most common somatic event in LT; however, the mechanisms by which TP53 mutations promote LT remai...

Oct 27th, 2021 - Megakaryocytes (MKs) are the unique non-pathological cells that undergo polyploidization in mammals. The polyploid formation is critical for understanding the MK biology, and transcriptional regulation is involved in the differentiation and matura...

Aug 31st, 2021 - Natural agents have been used to restart the process of differentiation that is inhibited during leukemic transformation of hematopoietic stem or progenitor cells. Autophagy is a housekeeping pathway that maintains cell homeostasis against stress ...

Aug 27th, 2021 - BET inhibitors enhance embryonic and fetal globin expression in erythroleukemia cell lines.|2021|Cao JZ,Bigelow K,Wickrema A,Godley LA,|genetics,drug therapy,genetics,metabolism,

Mar 3rd, 2020 - Background: During recent years, the cancer-testis (CT) antigens have emerged as attractive targets for cancer immunotherapy. Whereas lung and esophageal cancers, as well as malignant pleural mesotheliomas express a variety of CT antigens, immune ...

Mar 3rd, 2020 - Background: During recent years, the cancer-testis (CT) antigens (CTA) have emerged as attractive targets for cancer immunotherapy. Whereas malignancies of diverse histologies express a variety of CTAs, immune responses to these antigens appear un...

Apr 2nd, 2021 - Transcript:Vinod Pullarkat, MD: Hello, and thank you for joining us today for this OncLive Peer Exchange® on the topic of Myelodysplastic Syndrome: Managing Risk and Complications. Myelodysplastic syndrome is a heterogeneous disease that necessita...

Apr 18th, 2017 - Photo by Rhoda Baer Researchers in the lab A dual kinase inhibitor is active against a range of hematologic malignancies, according to preclinical research. Investigators found that ASN002, a SYK/JAK inhibitor, exhibited “potent” antiproliferative.